Current Studies

Volunteers change lives!

Women’s Health

Blood Test to Detect Breast Cancer

Boeson Research is currently evaluating the efficacy of a new blood test, developed by Toray Industries, that could more accurately distinguish women who are at increased risk for breast cancer from those who are not. This blood test applies an algorithm to serum miRNA extracted from a patient’s blood sample.

There is great interest in developing new non-invasive ways to determine which women with an abnormal mammogram should have a biopsy, especially with tests done on a blood sample. Blood tests like the one we are studying could help reduce the number of women advised to undergo additional procedures such as ultrasound, MRI, or even biopsy itself.

Mammography has been proven to decrease mortality from breast cancer. However, there are false positives which result in women having additional imaging tests and/or a breast biopsy to be sure the abnormality seen on imaging isn’t breast cancer.

Although this study does not change any care recommendations throughout the patient’s current treatment, it does have the potential to help women in the future get easier, less-invasive, more accurate breast cancer detection. This study aims to provide sufficient samples to demonstrate its efficacy in meeting or exceeding biopsy results.

Patients that meet the basic requirements may be eligible to participate in this easy but significant study. Participation requires only a single short visit in our lab to draw a small 10 mL blood sample within eight weeks before the scheduled biopsy AND the patient’s consent to share their de-identified imaging and pathology results. Qualified participants will receive at no cost study-related evaluations, physical exams, routine lab work and investigational medication. Compensation for time and travel may be available to those who qualify.

Participation will require:
Women 21 years old and older.
Radiologist classification of BI-RADS 3, 4 or 5 from a recent imaging study.
NO personal prior lifetime history of DCIS (ductal carcinoma in situ), LCIS (lobular carcinoma in situ), or any type of invasive or localized breast cancer.
Excepting certain skin cancers, 10 year disease-free and treatment-free from any other non-breast cancer.

For complete details, please call Boeson Research at 406-763-8833 today!

Boeson Research – Missoula

Boeson Research – Great Falls

More Info - Toray

Women’s Health

Maternal RSV Vaccination for Newborn Protection

Interested in a research studyvto see if an investigational vaccine could help protect your baby?

Boeson Research is currently enrolling expectant mothers in a vaccine trial to provide protection against RSV in their newborns.

RSV is an important cause of morbidity and mortality worldwide, with a substantial burden of disease borne by young infants. Rates of severe RSV illness are highest in infants <6 months of age, with a peak in hospitalization between 1 and 2 months of life, though the highest case-fatality rates are observed in the neonatal period (<1 month). Infants born prematurely and those with underlying cardiac or pulmonary disease are at further increased risk of severe clinical disease due to RSV.

No specific treatments for RSV exist, and available prophylactic measures (ie, RSV monoclonal antibody) are limited to use in only those infants at highest risk; additionally, use of available RSV prophylaxis can be cost-prohibitive. While active immunization against RSV in infants might be ideal, multiple efforts, extending over half a century, to develop a safe and effective RSV vaccine to protect infants from disease have yielded little success. The early peak of disease presents a further obstacle to an active vaccination strategy for infants. Given these challenges, maternal immunization to protect infants early in life offers an attractive strategy for infant disease prevention.

The RSV vaccine is being developed to prevent medically significant RSV-associated lower respiratory tract infections (LRTI) in infants by active immunization of pregnant women.

Patients that meet the study requirements may be eligible to participate in this significant study. Participation requires a screening visit, a single vaccination, and scheduled follow-up visits for mom and baby. Qualified participants will receive at no cost study-related evaluations, physical exams, routine lab work and investigational medication. Compensation for time and travel will be made available to those who qualify.

Participation will require:

  • Healthy women between 18 and 49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and
    other study procedures.
  • Receiving prenatal standard of care.
  • Determined by medical history, physical examination, screening laboratory assessment, and clinical judgment to be appropriate for inclusion in the study.

For complete details, please call Boeson Research at 406-763-8833 today!

Boeson Research – Missoula

Boeson Research – Great Falls

More Info - Savvy RSV